SuperworthFate Therapeutics EPS FATE
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$1.05
- Latest quarter, Q2 FY26
- −$0.25
- Fiscal year 2025
- −$1.15
Fate Therapeutics' earnings per share was −$1.05 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.25.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.15 | n/a |
| FY2024 | −$1.64 | n/a |
| FY2023 | −$1.64 | n/a |
| FY2022 | −$2.91 | n/a |
| FY2021 | −$2.23 | n/a |
| FY2020 | −$2.08 | n/a |
| FY2019 | −$1.43 | n/a |
| FY2018 | −$1.20 | n/a |
| FY2017 | −$1.02 | n/a |
| FY2016 | −$1.06 | n/a |
| FY2015 | −$1.21 | n/a |
| FY2014 | −$1.26 | n/a |
| FY2013 | −$12.48 | n/a |
| FY2012 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.25 | n/a | −$1.05 | |
| Q1 FY26 | −$0.26 | n/a | −$1.09 | |
| Q4 FY25 | −$0.27 | n/a | −$1.15 | |
| Q3 FY25 | −$0.27 | n/a | −$1.32 | |
| Q2 FY25 | −$0.29 | n/a | −$1.45 | |
| Q1 FY25 | −$0.32 | n/a | −$1.49 | |
| Q4 FY24 | −$0.44 | n/a | −$1.64 | |
| Q3 FY24 | −$0.40 | n/a | −$1.65 | |
| Q2 FY24 | −$0.33 | n/a | −$1.71 | |
| Q1 FY24 | −$0.47 | n/a | −$1.92 | |
| Q4 FY23 | −$0.45 | n/a | −$1.64 | |
| Q3 FY23 | −$0.46 | n/a | −$1.77 |
Against its peers
Companies in Biotechnology nearest Fate Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| FATEFate Therapeutics | −$1.05 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Fate Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.